269 related articles for article (PubMed ID: 34493150)
21. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I
Cancer Sci; 2023 Mar; 114(3):995-1006. PubMed ID: 36336963
[TBL] [Abstract][Full Text] [Related]
22. Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.
Janeczko-Czarnecka M; Krawczuk-Rybak M; Karpińska-Derda I; Niedźwiecki M; Musioł K; Ćwiklińska M; Drabko K; Mycko K; Ociepa T; Pawelec K; Januszkiewicz-Lewandowska D; Ussowicz M; Rybka B; Ryczan-Krawczyk R; Kołtan A; Karolczyk G; Zaucha-Prażmo A; Badowska W; Kałwak K
Adv Clin Exp Med; 2018 Jan; 27(1):91-98. PubMed ID: 29521048
[TBL] [Abstract][Full Text] [Related]
23. Outcome prediction of chronic myeloid leukemia (CML) in children.
Leung WY; Cheuk DK; Cheng FW; Leung AW; Chiu KH; Ho KK; Li CH; Chan GC
Ann Hematol; 2022 Aug; 101(8):1677-1688. PubMed ID: 35641639
[TBL] [Abstract][Full Text] [Related]
24. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
26. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio.
Erkek ET; Isik AC; Ipek Y; Kul AN
Niger J Clin Pract; 2023 Jun; 26(6):802-809. PubMed ID: 37470656
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Eşkazan AE; Özmen D; Öztaş M; Bektaş F; Bayraktar EA; Sadri S; Keskin D; Özgür Yurttaş N; Elverdi T; Salihoğlu A; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):549-557. PubMed ID: 34052176
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Whiteley J; Iyer S; Candrilli SD; Kaye JA
Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
[TBL] [Abstract][Full Text] [Related]
31. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
32. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
[No Abstract] [Full Text] [Related]
33. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.
Chen MT; Huang ST; Lin CW; Ko BS; Chen WJ; Huang HH; Hsiao FY
Oncologist; 2021 Nov; 26(11):974-982. PubMed ID: 34418220
[TBL] [Abstract][Full Text] [Related]
34. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
35. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
[TBL] [Abstract][Full Text] [Related]
36. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.
Alonso-Dominguez JM; Grinfeld J; Alikian M; Marin D; Reid A; Daghistani M; Hedgley C; O'Brien S; Clark RE; Apperley J; Foroni L; Gerrard G
Am J Hematol; 2015 Jan; 90(1):20-6. PubMed ID: 25250944
[TBL] [Abstract][Full Text] [Related]
37. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
38. Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Ni J; Hong J; Zhang Z; Li Q; Xia R; Zeng Q; Sun G
Leuk Lymphoma; 2020 May; 61(5):1195-1200. PubMed ID: 31858854
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
40. Complexity of chronic-phase CML management after failing a second-generation TKI.
El Fakih R; Chaudhri N; Alfraih F; Rausch CR; Naqvi K; Jabbour E
Leuk Lymphoma; 2020 Apr; 61(4):776-787. PubMed ID: 31739705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]